Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

June 2021	Phase I/II Updated Safety and Efficacy Results of Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Relapsed/Refractory Immune Thrombocytopenia Dr. David Kuter et al. European Hematology Association Oral Presentation, June 14, 2021
May 2021	Proof-of-concept for clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study Dr. Deedee Murrell et al. British Journal of Dermatology, May 2021
April 2021	Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid Use and Improved Quality of Life in Patients With Chronic Relapsing Pemphigus: BELIEVE Phase 2 Study (Part A) Dr. Deedee Murrell et al. AAD Oral Presentation, April 23, 2021
March 2021	Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease Dr. Claire Langrish et al. Journal of Immunology, March 5, 2021
December 2020	Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients With Heavily Pretreated Immune Thrombocytopenia Dr. David Kuter et al. ASH Oral Presentation, December 5, 2020
October 2020	Mechanisms of Topical Bruton Tyrosine Kinase Inhibitor PRN473 in Immune‑Mediated Models of Skin Disease Dr. Yan Xing et al. EADV Poster Presentation, October 29, 2020
October 2020	Metabolism-Mediated Drug Interactions Between Ritonavir and Oral BTK Inhibitor Rilzabrutinib in Rats Dr. Sibel Ucpinar et al. ACCP Poster Presentation, October 27, 2020
October 2020	A Thorough QT Study to Evaluate the Effects of Oral Rilzabrutinib Administered Alone and With Ritonavir to Achieve Supratherapeutic Concentrations in Healthy Subjects Dr. Sibel Ucpinar et al. ACCP Poster Presentation, October 27, 2020

Advancing Promising Therapies

See Our Pipeline